Multidrug resistance protein P-glycoprotein and its Inhibitors.doc

 PAGE \* MERGEFORMAT 18 Multidrug resistance protein P-glycoprotein and its Inhibitors [Abstract] effect of chemotherapy in pancreatic tumor cells is not satisfactory mainly due to multidrug resistance. Multidrug resistance in pancreatic cancer cells generating mechanism is not currently clear, as the multidrug resistance of deeper understanding and new The reversal agent has been generated. In this paper, recent literature review of 5-year review of resistance mechanisms of pancreatic cancer and its Inhibitors reviewed. [Keywords:] P-glycoprotein; inhibitor; multi-drug resistant Tumor therapy is the current hotspot, chemotherapy is the current primary means of treatment of malignant tumors, but tumor cells to chemotherapy of multidrug resistance (MDR) is a major obstacle to cancer treatment, but also the majority of cancer patients with poor prognosis main reasons. present a large number of studies have shown that tumor cells produce the causes and mechanisms of MDR are complex, multi-drug resistance protein P-glycoprotein-mediated multidrug resistance in the most important and most representative, P-glycoprotein inhibition Agent has become a hotspot in recent years. 1 P-glycoprotein structure P - glycoprotein (P-lycoprotein, P-gp) is an enzyme adenosine triphosphate (ATP enzyme), is energy dependent membrane binding protein, belonging to ATP binding cassette (ABC) transporter [1]. It consists of 1280 amino acids, expressed by a single chain. This single strand is divided into 2 equal length homologous subunits, each subunit consists of six transmembrane domains and two ATP binding peptide separated by a zone separated , the connector region of P-gp for the secondary structure of the two subunits have enough coordination function, such coordination functions may require two ATP binding sites of interaction [2]. ATP binding in the cytoplasm side of the that the nucleotide binding fold, nucleotide binding fold in the cytoplasm, the substrate for t